Business Context and Reporting Period
This Form 6-K filing by BioBlast Pharma Ltd. (also referenced as Enlivex Ltd. in metadata) covers the month of September 2015, specifically dated September 14, 2015. The report serves to disclose a press release announcing a significant regulatory milestone: the grant of a patent by the United States Patent and Trademark Office (USPTO) for the company's product candidate, Cabaletta, for the treatment of Spinocerebellar Ataxia (SCA).
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate event (patent grant) and does not contain financial statements or quantitative financial data.
Material Changes
The material change disclosed is the successful acquisition of a US patent for Cabaletta targeting Spinocerebellar Ataxia. No financial comparisons to prior periods are included in this document.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the patent grant. The filing does not provide specific financial guidance, future outlook projections, or a detailed discussion of risks and contingencies beyond the context of the patent achievement.
Key Facts for Investor Verification
- Verify the specific scope and claims of the USPTO patent granted for Cabaletta regarding Spinocerebellar Ataxia.
- Confirm the current clinical development status of Cabaletta following this patent grant.
- Review subsequent filings for financial updates, as this document contains no financial data.
- Validate the company's name usage, noting the registrant is listed as BioBlast Pharma Ltd. in the filing text while metadata references Enlivex Ltd.